History of the Labo’Life Group
Labo’Life France was founded in 1992 by Mr. Christian Foissey with the help of a French private shareholding and, in December, the first production unit of the Labo’Life group was set up in Consell (Mallorca). The production was launched in August 1993 when Labo’Life España received the authorization for the manufacture of medicines for human use from the Spanish Agency for Medicines and Sanitary Products (AEMPS). Between June and July 2000 Labo’Life Belgium and Labo’Life Italia (Milan) were created, with a new pharmaceutical distribution unit in Belgium. In 2004, Labo’Life Belgium, located at the Crealys Science Park in Gembloux, became a production laboratory.
Medicine Production Department
Micro-immunotherapy medicines are manufactured by Labo’Life’s Medicine Production Department. Once analyzed by the quality control laboratory and released (verification of their compliance) by the responsible pharmacist, the active substances of the medicine (cytokines, nucleic acids, etc.) and the packaging materials can integrate the GMP production process
R+D and Active Ingredients Production Department (AIP)
R+D and Active Ingredients Production Department (AIP) is responsible for the development and optimization of biotechnology processes for the extraction and purification of cytokines used in Labo’Life medicines.
Clinical Evaluations Department
The Clinical Evaluation Department has a dual mission:
- Collect and analyze clinical data from prescribing physicians in retrospective studies, especially for the scientific recognition of micro-immunotherapy.
- Set up prospective studies versus placebo or control group, meeting the Standards of Good Clinical Practice and validated by health authorities and ethics committees, to confirm the effectiveness of Labo’Life medicines.